ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

WuXi Biologics plans its first US manufacturing facility near Boston

by Rick Mullin
May 21, 2020 | APPEARED IN VOLUME 98, ISSUE 20

WuXi Biologics says it will build a $60 million biologics discovery, development, and manufacturing center in Worcester, Massachusetts. WuXi expects the 9,940 m2 facility, its first biologics plant in the US, to open in 2022. The Chinese firm says the plant will have 4,500 L of bioreactor capacity and employ about 150 people. It will run with continuous bioprocessing, deploying single-use reactors for clinical and small-volume commercial production.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment